BMS-Pfizer Alliance partners with Mark Cuban Cost Plus Drugs to expand eliquis access

In a significant move for pharmaceutical transparency, the Bristol Myers Squibb-Pfizer Alliance announced that Eliquis® (apixaban), one of the world’s most widely prescribed blood thinners, will soon be available through Mark Cuban’s direct-to-consumer pharmacy.

The collaboration, announced Friday, will make Eliquis available on CostPlusDrugs.com beginning April 27, 2026.

Cash-paying patients with a valid prescription will be able to purchase a 30-day supply for $345.

While this remains a premium price point compared to many generic offerings on the platform, it represents one of the most high-profile brand-name integrations for the Cost Plus Drugs model, which bypasses traditional middle-tier pharmacy benefit managers (PBMs) to offer simplified pricing.

Mark Cuban, co-founder of Cost Plus Drugs, noted that Eliquis has been among the most requested medications from his customer base.

The timing of the launch is strategic.

Eliquis was among the first ten drugs selected for price negotiations under the U.S. Inflation Reduction Act, with new negotiated prices set to take effect in early 2027.